GSK_Annual_Report_2021

Annual Report 2020-21 163 The Company has adequate cash and bank balances and no interest bearing liabilities. The company monitors its capital by a careful scrutiny of the cash and bank balances, and a regular assessment of any debt requirements. In the absence of any interest bearing debt, the maintenance of debt equity ratio etc. may not be of any relevance to the Company. 28 SEGMENT REPORTING An operating segment is one whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The Company has identified the Chief Operating Decision Maker as its Director. The Chief Operating Decision Maker reviews performance of pharmaceutical business on an overall basis. As the Company has a single reportable segment, the segment wise disclosure requirements of Ind AS 108 on Operating Segment is not applicable. In compliance to the said standard, Entity-Wide disclosures are as under : ` in Lakhs Year ended March 31, 2021 Year ended March 31, 2020 Revenues from external customers attributed to the country of domicile and attributed to all foreign countries from which the company derives revenues Revenue from the Country of Domicile- India 3,23.43 - Revenue from foreign countries 9,32.79 - Total 12,56.22 - ` in Lakhs Year ended March 31, 2021 Year ended March 31, 2020 Details of non current asset Non Current asset from the Country of Domicile- India 5,76.45 3,17.53 Non Current asset from foreign countries - - Total 5,76.45 3,17.53 29 RELATED PARTY DISCLOSURES 1 Related parties with whom there were transactions during the year are listed below: Holding Company: - The company is a wholly owned subsidiary of GlaxoSmithKline Pharmaceuticals Limited. Other related parties in the GlaxoSmithKline (GSK) Group where common control exists - GSK Export Limited - GSK Asia Private Limited - Stiefel India Private Limited 2 The following transactions were carried out with the related parties at normal commercial terms in the ordinary course of business. ` in Lakhs Holding Company Year Ended 31 st March, 2021 Year Ended 31 st March, 2020 GlaxoSmithKline Pharmaceuticals Limited 1. Payment of common costs 25.33 29.95 2. Sale of products 3,23.43 - 3. Payment of Manufacturing charges 3,94.87 - 4. Outstanding receivable / (Payable) by the Company (net)* (3,94.16) 44.02 ` in Lakhs Other related parties in the GlaxoSmithKline (GSK) Group where common control exists Year Ended 31 st March, 2021 ** Year Ended 31 st March, 2021 Year Ended 31 st March, 2020 Year Ended 31 st March, 2021 Year Ended 31 st March, 2020 GSK Asia Private Limited GSK Export Limited Stiefel India Private Limited 1. Purchase of raw materials 10,52.62 - - - - 2. Sale of products - 9,32.79 - - - 3. Outstanding receivable / (Payable) by the Company (net)* - 10,44.72 - - (0.59) * Transactions with the above parties are accounted in the respective current accounts. ** No transactions for the year ended 31 st March, 2020 30 In view to make financial statements comparable, previous period’s figures have been regrouped wherever necessary. As per our report of even date attached For and on behalf of the Board For CORNELIUS & DAVAR CHARTERED ACCOUNTANTS (Firm’s Registration No.101963W) Sridhar Venkatesh Director DIN: 07263117 Puja Thakur Director DIN: 07971789 RUSTOM D. DAVAR (PARTNER) Membership No. F10620 Place : Mumbai Date: May 10, 2021 UDIN: 21010620AAAABG3059 Rohan Mota Company Secretary ACS 38473